Literature DB >> 7612150

Insulin-secretory-granule specific T cell clones in human IDDM.

J C Chang1, L G Linarelli, J A Laxer, K J Froning, L L Caralli, S W Brostoff, D J Carlo.   

Abstract

T cell clones reactive to beta-cell antigens prepared from different species were established in order to identify putative pathogenic T cells in human IDDM. We were able to generate T cell clones from patients, but not from controls, reactive specifically to the insulin secretory enriched fraction (ISG) of a rat insulinoma RIN cell line. This finding is suggestive of an in vivo priming by the antigen(s). To examine the relevance of these T cell clones in the pathogenesis of IDDM, we studied their cytokine profile. T cell clones from the newly onset patients had a Th1 cytokine profile, while those from the prediabetic patient were of the Th2 subtype. This segregation suggests that RIN-ISG contains antigen(s) involved in the pathogenesis of this disease, since IDDM is considered a cell-mediated or Th1 disease. Since two of these clones also responded to a hamster insulinoma cell line HIT, at least two antigens in RIN-ISG could be defined by this panel of T cell clones. Examination of CDR3 sequences confirmed the clonality of the dual-reactive T cell clones. The finding of HIT-reactive cells in IDDM patients may be useful in efforts to identify prediabetic patients for immune intervention. Dual reactivity may provide a better prognosis than single reactivity. In contrast to T cell clones reactive to insulinomas, T cell clones reactive to normal human ISG were not found after over 200 clones were screened. In addition, RIN-ISG specific clones did not respond to either normal human or rat ISG, suggesting that IDDM antigens are below detectable levels in normal beta cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612150     DOI: 10.1006/jaut.1995.0017

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  3 in total

1.  Evidence for recognition of novel islet T cell antigens by granule-specific T cell lines from new onset type 1 diabetic patients.

Authors:  T I Tree; D O'Byrne; J M Tremble; W M MacFarlane; K Haskins; R F James; K Docherty; J C Hutton; J P Banga
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

Review 2.  Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.

Authors:  A E Barcala Tabarrozzi; C N Castro; R A Dewey; M C Sogayar; L Labriola; M J Perone
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

3.  Imogen 38: a novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient.

Authors:  S D Arden; B O Roep; P I Neophytou; E F Usac; G Duinkerken; R R de Vries; J C Hutton
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.